Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Biol Interact ; 229: 64-72, 2015 Mar 05.
Article in English | MEDLINE | ID: mdl-25641192

ABSTRACT

It has been reported that various metal coordination compounds have improved some biological properties. A high activity of acid phosphatase (AcP) is associated to several diseases (osteoporosis, Alzheimer's, prostate cancer, among others) and makes it a target for the development of new potential inhibitors. Anti-thyroid agents have disadvantageous side effects and the scarcity of medicines in this area motivated many researchers to synthesize new ones. Several copper(II) complexes have shown antifungal activities. In this work we presented for a first time the inhibition of AcP and the anti-thyroid activity produced by methimazole-Cu(II) complexes. Cu-Met ([Cu(MeimzH)2(H2O)2](NO3)2·H2O) produces a weak inhibition action while Cu-Met-phen ([Cu(MeimzH)2(phen)(H2O)2]Cl2) shows a strong inhibition effect (IC50 = 300 µM) being more effective than the reported behavior of vanadium complexes. Cu-Met-phen also presented a fairly good anti-thyroid activity with a formation constant value, Kc=1.02 × 10(10)M(-1) being 10(6) times more active than methimazole (Kc = 4.16 × 10(4)M(-1)) in opposition to Cu-Met which presented activity (Kc=9.54 × 10(3)M(-1)) but in a lesser extent than that of the free ligand. None of the complexes show antifungal activity except Cu-phen (MIC = 11.71 µgmL(-1) on Candidaalbicans) which was tested for comparison. Besides, albumin interaction experiments denoted high affinity toward the complexes and the calculated binding constants indicate reversible binding to the protein.


Subject(s)
Acid Phosphatase/antagonists & inhibitors , Antifungal Agents/pharmacology , Antithyroid Agents/pharmacology , Coordination Complexes/pharmacology , Copper/pharmacology , Methimazole/pharmacology , Serum Albumin, Bovine/metabolism , Acid Phosphatase/metabolism , Animals , Antifungal Agents/chemistry , Antithyroid Agents/chemistry , Candida/drug effects , Candidiasis/drug therapy , Cattle , Coordination Complexes/chemistry , Copper/chemistry , Humans , Methimazole/chemistry , Protein Conformation/drug effects , Serum Albumin, Bovine/chemistry
2.
Biometals ; 23(2): 255-64, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20012553

ABSTRACT

Methimazole (MeimzH) is an anti-thyroid drug and the first choice for patients with Grave's disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)(2)(NO(3))(2)]*0.5H(2)O and [Cu(MeimzH)(2)(H(2)O)(2)](NO(3))(2)*H(2)O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.


Subject(s)
Alkaline Phosphatase/antagonists & inhibitors , Antithyroid Agents/chemical synthesis , Antithyroid Agents/metabolism , Antithyroid Agents/therapeutic use , Copper/chemistry , Graves Disease/drug therapy , Methimazole/chemical synthesis , Methimazole/metabolism , Methimazole/therapeutic use , Animals , Antithyroid Agents/chemistry , Electron Spin Resonance Spectroscopy , Humans , Methimazole/chemistry , Spectrophotometry, Ultraviolet , Spectroscopy, Fourier Transform Infrared
SELECTION OF CITATIONS
SEARCH DETAIL
...